Revolutionary CAR-T cell therapies for blood cancer could be on the European market within a few months after they were given the green light by regulators – but they face further price scr
The American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance in cancer therapy this year – and latest clinical trial results from t
